Lactoferrin Supplementation in Preventing and Protecting from SARS-CoV-2 Infection: Is There Any Role in General and Special Populations? An Updated Review of Literature
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms251910248 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Paolo Manzoni und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Maternal, Neonatal and Infant Medicine, University Hospital "Degli Infermi", 13875 Ponderano, Italy. Hauptthemen laut MEDLINE: Lactoferrin, Dietary Supplements, COVID-19, SARS-CoV-2. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 145 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
At the beginning of the pandemic, SARS-CoV-2 infection represented a great medical burden worldwide, as targeted and effective therapeutic options were lacking. This resulted in the revival of existing molecules and the increasing popularity of over-the-counter nutritional supplements. Among the latter, lactoferrin has been investigated as an adjuvant in COVID-19 therapy with conflicting results, mainly depending on different study designs. Considering that lactoferrin is one of the main components of human breast milk with anti-microbial and anti-inflammatory activity, it is conceivable that such bioactive molecule could be effective in supporting anti-SARS-CoV-2 infection therapy, especially in infants and pregnant women, two subpopulations that have been poorly evaluated in the existing clinical trials. This narrative review is intended to offer insight into the existing literature on lactoferrin’s biological functions and protective effects against COVID-19, with a special focus on pregnant women and their infants.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Maternal, Neonatal and Infant Medicine, University Hospital "Degli Infermi", 13875 Ponderano, Italy.
- School of Medicine, University of Turin, 10124 Turin, Italy.
- Sant'Anna Hospital, Department of Surgical Sciences, University of Turin, 10126 Turin, Italy.
- Neonatology and Neonatal Intensive Care Unit, Policlinico Casilino, 00169 Rome, Italy.
- Department of Translational Medicine (DiMeT), Università del Piemonte Orientale (UPO), 28100 Novara, Italy.
- IRCAD (Interdisciplinary Research Center of Autoimmune Diseases), Università del Piemonte Orientale (UPO), 28100 Novara, Italy.
ORCID-Profile: Paolo Manzoni, Alessandro Messina, Chiara Germano, Bianca Masturzo, Pier Paolo Sainaghi, Daniele Sola, Manuela Rizzi
Zitieren
APA
Manzoni, P., Messina, A., Germano, C., Picone, S., Masturzo, B., Sainaghi, P. P., Sola, D., & Rizzi, M. (2024). Lactoferrin Supplementation in Preventing and Protecting from SARS-CoV-2 Infection: Is There Any Role in General and Special Populations? An Updated Review of Literature. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms251910248
Vancouver
Manzoni P, Messina A, Germano C, Picone S, Masturzo B, Sainaghi PP, et al. Lactoferrin Supplementation in Preventing and Protecting from SARS-CoV-2 Infection: Is There Any Role in General and Special Populations? An Updated Review of Literature. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms251910248
BibTeX
@article{Manzoni2024,
author = {Manzoni, Paolo and Messina, Alessandro and Germano, Chiara and Picone, Simonetta and Masturzo, Bianca and Sainaghi, Pier Paolo and Sola, Daniele and Rizzi, Manuela},
title = {Lactoferrin Supplementation in Preventing and Protecting from SARS-CoV-2 Infection: Is There Any Role in General and Special Populations? An Updated Review of Literature},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms251910248}
}
EUVIMED